(Total Views: 205)
Posted On: 03/28/2017 12:00:00 PM
Post# of 273336
AXSM (MC $83 M)(Cash $50 M) 5x BIG Phase 3 in various indications targeting large Markets with first interim results in 2H 2017
Undiscovered and terrible undervalued Biotech Stock with many Major News on the way . Axsome has 5 Phase 3 clinical trials ongoing in various indication targeting very large Markets .This Stock is brutally undervalued with Market cap of $92 million and $50 million in cash .Founder and Ceo is the larget shareholder holding over 7 million shares (30%) over 50% of O/S is owned by Insider and Institutions which is a good sign .
This undiscovered goldmine could be the next 10 bagger gem if just oneof their 5 Phase 3 program is successful .GL
Axsome (AXSM)
Market-Cap: $92 Million
Cash: $50.6 Million
Price:$4
Shares Out: 23 Million
Anticipated Near-Term Clinical Milestones
Clinical Trial Initiations: -- Phase 2/3 clinical trial of AXS-05 in AD agitation (2Q 2017)
Clinical Trial Readouts:
-- Phase 3 COAST-1 trial of AXS-02 in knee OA associated with BMLs, interim analysis (3Q 2017)
-- Phase 3 CREATE-1 trial of AXS-02 in CRPS, interim efficacy analysis (4Q 2017)
-- Phase 3 STRIDE-1 trial of AXS-05 in TRD, top-line data (1Q 2018)
New Presentation
media.corporate-ir.net/media_files/IROL/25/254022/Axsome_Presentation_14_Mar_2017.pdf
Major Shareholders
Herriott Tabuteau, MD 7 351 729 38,4%
Fidelity Management & Research Co. 2 361 625 12,3%
JPMorgan Asset Management (UK) Ltd. 1 432 456 7,48%
Mark Coleman, MD 647 998 3,38%
BlackRock Fund Advisors 426 837 2,23%
Stifel Trust Co., NA 415 279 2,17%
The Vanguard Group, Inc. 272 189 1,42%
Lombard Odier Asset Management (USA) Corp. 250 000 1,31%
JPMorgan Investment Management, Inc. 156 625 0,82%
SSgA Funds Management, Inc. 134 688 0,70%
Undiscovered and terrible undervalued Biotech Stock with many Major News on the way . Axsome has 5 Phase 3 clinical trials ongoing in various indication targeting very large Markets .This Stock is brutally undervalued with Market cap of $92 million and $50 million in cash .Founder and Ceo is the larget shareholder holding over 7 million shares (30%) over 50% of O/S is owned by Insider and Institutions which is a good sign .
This undiscovered goldmine could be the next 10 bagger gem if just oneof their 5 Phase 3 program is successful .GL
Axsome (AXSM)
Market-Cap: $92 Million
Cash: $50.6 Million
Price:$4
Shares Out: 23 Million
Anticipated Near-Term Clinical Milestones
Clinical Trial Initiations: -- Phase 2/3 clinical trial of AXS-05 in AD agitation (2Q 2017)
Clinical Trial Readouts:
-- Phase 3 COAST-1 trial of AXS-02 in knee OA associated with BMLs, interim analysis (3Q 2017)
-- Phase 3 CREATE-1 trial of AXS-02 in CRPS, interim efficacy analysis (4Q 2017)
-- Phase 3 STRIDE-1 trial of AXS-05 in TRD, top-line data (1Q 2018)
New Presentation
media.corporate-ir.net/media_files/IROL/25/254022/Axsome_Presentation_14_Mar_2017.pdf
Major Shareholders
Herriott Tabuteau, MD 7 351 729 38,4%
Fidelity Management & Research Co. 2 361 625 12,3%
JPMorgan Asset Management (UK) Ltd. 1 432 456 7,48%
Mark Coleman, MD 647 998 3,38%
BlackRock Fund Advisors 426 837 2,23%
Stifel Trust Co., NA 415 279 2,17%
The Vanguard Group, Inc. 272 189 1,42%
Lombard Odier Asset Management (USA) Corp. 250 000 1,31%
JPMorgan Investment Management, Inc. 156 625 0,82%
SSgA Funds Management, Inc. 134 688 0,70%
(0)
(0)
